ATNM – Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. ATNM
$1.54Name : Actinium Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $48,272,036.00
EPSttm : 0.36
Actinium Pharmaceuticals, Inc.
$1.54
2.28%$0.035
ATNM — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.04
Margin Of Safety %
Put/Call OI Ratio
0.01
EPS Next Q Diff
-1.12
EPS Last/This Y
1.23
EPS This/Next Y
-0.66
Price
1.56
Target Price
3.67
Analyst Recom
1
Performance Q
89.99
Upside
200.0%
Beta
0.26
Ticker: ATNM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | ATNM | 1.04 | 0.00 | 0.00 | 3434 |
| 2026-10-13 | ATNM | 0.9977 | 0.00 | 0.00 | 3444 |
| 2026-10-14 | ATNM | 0.968 | 0.00 | 0.00 | 3445 |
| 2026-10-15 | ATNM | 1.06 | 0.00 | 0.00 | 3453 |
| 2026-10-16 | ATNM | 1.12 | 0.00 | 0.00 | 3466 |
| 2026-10-19 | ATNM | 1.32 | 0.00 | 0.00 | 3431 |
| 2026-10-20 | ATNM | 1.4 | 0.00 | 0.00 | 3484 |
| 2026-10-21 | ATNM | 1.39 | 0.00 | 0.00 | 3709 |
| 2026-10-22 | ATNM | 1.59 | 0.00 | 0.00 | 3769 |
| 2026-10-23 | ATNM | 1.52 | 0.00 | 0.00 | 3978 |
| 2026-10-26 | ATNM | 1.4 | 0.00 | 0.00 | 3983 |
| 2026-10-27 | ATNM | 1.435 | 0.00 | 0.09 | 3985 |
| 2026-10-28 | ATNM | 1.42 | 0.00 | 0.05 | 4099 |
| 2026-10-29 | ATNM | 1.535 | 0.00 | 0.00 | 4107 |
| 2026-10-30 | ATNM | 1.485 | 0.00 | 0.00 | 4107 |
| 2026-11-02 | ATNM | 1.44 | 0.00 | 0.00 | 4111 |
| 2026-11-03 | ATNM | 1.42 | 0.00 | 999.99 | 4159 |
| 2026-11-04 | ATNM | 1.42 | 0.01 | 0.00 | 4169 |
| 2026-11-05 | ATNM | 1.325 | 0.01 | 0.00 | 4197 |
| 2026-11-06 | ATNM | 1.41 | 0.01 | 0.00 | 4207 |
| 2026-11-09 | ATNM | 1.56 | 0.01 | 0.00 | 4571 |
| 2026-11-10 | ATNM | 1.56 | 0.01 | 0.00 | 5779 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | ATNM | 1.03 | -59.4 | - | 0.14 |
| 2026-10-13 | ATNM | 1.00 | -59.4 | - | 0.14 |
| 2026-10-14 | ATNM | 0.96 | -59.4 | - | 0.14 |
| 2026-10-15 | ATNM | 1.05 | -59.4 | - | 0.14 |
| 2026-10-16 | ATNM | 1.12 | -59.4 | - | 0.14 |
| 2026-10-19 | ATNM | 1.33 | -59.4 | - | 0.14 |
| 2026-10-20 | ATNM | 1.33 | -59.4 | - | 0.14 |
| 2026-10-21 | ATNM | 1.40 | -59.4 | - | 0.14 |
| 2026-10-22 | ATNM | 1.59 | -59.4 | - | 0.14 |
| 2026-10-23 | ATNM | 1.50 | -59.4 | - | 0.14 |
| 2026-10-26 | ATNM | 1.38 | -59.4 | - | 0.14 |
| 2026-10-27 | ATNM | 1.43 | -59.4 | - | 0.14 |
| 2026-10-28 | ATNM | 1.42 | -59.4 | - | 0.14 |
| 2026-10-29 | ATNM | 1.54 | -59.4 | - | 0.14 |
| 2026-10-30 | ATNM | 1.47 | -59.4 | - | 0.14 |
| 2026-11-02 | ATNM | 1.43 | -59.4 | - | 0.14 |
| 2026-11-03 | ATNM | 1.40 | -59.4 | - | 0.14 |
| 2026-11-04 | ATNM | 1.42 | -59.4 | - | 0.14 |
| 2026-11-05 | ATNM | 1.30 | -59.4 | - | 0.14 |
| 2026-11-06 | ATNM | 1.41 | -59.4 | - | 0.14 |
| 2026-11-09 | ATNM | 1.54 | -59.4 | - | 0.14 |
| 2026-11-10 | ATNM | 1.56 | -59.4 | - | 0.14 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | ATNM | 0.00 | -0.03 | 2.29 |
| 2026-10-13 | ATNM | 0.00 | -0.03 | 2.29 |
| 2026-10-14 | ATNM | 0.00 | -0.03 | 2.29 |
| 2026-10-15 | ATNM | 0.00 | -0.03 | 2.29 |
| 2026-10-16 | ATNM | 0.00 | -0.03 | 2.29 |
| 2026-10-19 | ATNM | 0.00 | -0.04 | 2.29 |
| 2026-10-20 | ATNM | 0.00 | -0.04 | 2.29 |
| 2026-10-21 | ATNM | 0.00 | -0.04 | 2.29 |
| 2026-10-22 | ATNM | 0.00 | -0.04 | 2.29 |
| 2026-10-23 | ATNM | 0.00 | -0.04 | 2.29 |
| 2026-10-26 | ATNM | 0.00 | -0.11 | 2.29 |
| 2026-10-27 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-10-28 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-10-29 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-10-30 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-11-02 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-11-03 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-11-05 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-11-06 | ATNM | 0.00 | -0.11 | 2.04 |
| 2026-11-09 | ATNM | 0.00 | -2.71 | 2.04 |
| 2026-11-10 | ATNM | 0.00 | -2.71 | 2.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.89
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
Institutional Transactions
-2.71
Beta
0.26
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
72
Growth Score
27
Sentiment Score
42
Actual DrawDown %
89.7
Max Drawdown 5-Year %
-94.8
Target Price
3.67
P/E
4.37
Forward P/E
PEG
P/S
1.4
P/B
1.62
P/Free Cash Flow
EPS
0.36
Average EPS Est. Cur. Y
0.14
EPS Next Y. (Est.)
-0.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.23
Relative Volume
0.93
Return on Equity vs Sector %
11
Return on Equity vs Industry %
30.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
ATNM
Healthcare
$1.56
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
61.9
Range 1M
83.1%
Sup Dist
7.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
116.2%
EPS NY
-420.8%
52W%
81.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+135.3% upside
Upside
+135.3%
Quality
72
ATNM — P/E HistoricalBiotechnology
Actinium Pharmaceuticals, Inc. Sector: Healthcare
Industry: Biotechnology
Employees: 27
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
ATNM
Latest News
—
Caricamento notizie per ATNM…
stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today
news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance
stock history ATNM – Actinium Pharmaceuticals Inc invest stock market
stock prices ATNM premarket after hours
ticker ATNM fair value insiders trading